Nexletol Market Report 2026

Nexletol Market Overview

• Nexletol market size has reached to $3.21 billion in 2025 • Expected to grow to $6.07 billion in 2030 at a compound annual growth rate (CAGR) of 13.5% • Growth Driver: Surge In Cardiovascular Deaths Fueling The Growth Of The Market Due To High LDL-Driven Risk • Market Trend: Advances In Oral Cholesterol-Lowering Technologies Accelerate Market Momentum • North America was the largest region in 2025.

What Is Covered Under Nexletol Market?

Nexletol is a medication that works by targeting and inhibiting a specific enzyme involved in the production of cholesterol in the liver. The primary purpose of Nexletol (generic name: bempedoic acid) is to lower low-density lipoprotein cholesterol (LDL-C), commonly referred to as bad cholesterol, in adults with specific cardiovascular conditions. The main types of nextol include 180mg and other types. 180mg refers to a specific dosage of a medication, typically used to describe the amount of the active ingredient per dose. The administration routes include oral, injectable, and intravenous and it is used for various indications such as hyperlipidemia, atherosclerosis, and cardiovascular disease. It is used by several end-users such as hospitals, clinics, and homecare settings.

What Is The Nexletol Market Growth Forecast?

The nexletol market size is expected to see rapid growth in the next few years. It will grow to $6.07 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to introduction of bempedoic acid-based therapies, expansion of homecare and long-term care medication delivery, rising cardiovascular disease incidence, growing focus on combination therapies, increasing healthcare infrastructure in emerging markets. Major trends in the forecast period include rising adoption of ldl-c lowering therapies, increasing use of oral administration over injectable forms, expansion of cardiovascular disease awareness programs, growth in prescription-based and otc availability, integration of homecare and long-term care settings for medication use.

Global Nexletol Market Segmentation

1) By Type: 180mg, Other Types 2) By Administration Route: Oral, Injectable, Intravenous 3) By Indication: Hyperlipidemia, Atherosclerosis, Cardiovascular Disease 4) By End User: Hospitals, Clinics, Homecare Settings Subsegments: 1) By 180 mg: Prescription-based, Over-The-Counter (OTC), Hospital or clinic use, Long-Term care facilities use 2) By Other Types: 40 mg, 80 mg, Other doses

What Is The Driver Of The Nexletol Market?

The increasing cases of cardiovascular diseases are expected to propel the growth of the nexletol market going forward. Cardiovascular diseases refer to a group of disorders that affect the heart and blood vessels, including conditions like coronary artery disease, heart failure, and stroke. Cardiovascular diseases are rising due to increasingly sedentary lifestyles, as lack of physical activity leads to weight gain, metabolic imbalances, and higher blood pressure, all of which significantly elevate heart disease risk. Nexletol is beneficial for cardiovascular diseases as it lowers low-density lipoprotein (LDL) cholesterol levels, which helps reduce the buildup of plaque in arteries and lowers the risk of heart attacks and other cardiovascular events. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the increasing cases of cardiovascular diseases will boost the growth of the nexletol industry.

Key Players In The Global Nexletol Market

Major companies operating in the nexletol market are Esperion Therapeutics Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Recordati S.p.A., Almirall S.A., Menarini Group, Les Laboratoires Servier, Torrent Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Limited, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Hetero Drugs Limited, Alkem Laboratories Limited, Wockhardt Limited, Mylan (Viatris Inc.), Teva Pharmaceutical Industries Limited, Apotex Inc., Hikma Pharmaceuticals PLC, Krka d.d., STADA Arzneimittel AG, Sandoz International GmbH

Global Nexletol Market Trends and Insights

Major companies operating in the nexletol market are increasingly focusing on developing innovative oral non-statin LDL-cholesterol lowering therapies, such as bempedoic acid-based agents, to address the growing demand driven by the limitations of statins. Bempedoic acid–based agents are oral cholesterol-lowering drugs that inhibit ATP citrate lyase (ACL), an enzyme involved in the liver’s cholesterol-production pathway, thereby reducing LDL cholesterol; they help patients, especially those who cannot tolerate statins, by lowering LDL-C through a liver-selective mechanism that avoids the muscle-related side effects often associated with traditional statins. For instance, in March 2024, Esperion Therapeutics, Inc., a U.S.-based biopharmaceutical company, received FDA approval for a broad label expansion of its drugs Nexletol (bempedoic acid) and Nexlizet (bempedoic acid + ezetimibe), enabling their use for cardiovascular risk reduction and LDL-C lowering in both primary and secondary prevention regardless of statin use. Nexletol is a once-daily oral tablet formulated with bempedoic acid; it inhibits ACL to lower LDL-C and inflammation, has demonstrated reductions in major cardiovascular events in the CLEAR Outcomes trial, and offers a differentiated, non-statin oral alternative with a favorable safety profile. The updated label significantly widens U.S. patient eligibility, strengthening market adoption.

What Are Latest Mergers And Acquisitions In The Nexletol Market?

In May 2025, HLS Therapeutics, a Canada-based pharmaceutical company, partnered with Esperion Therapeutics to commercialize Nexletol. With this partnership, HLS Therapeutics aims to expand the availability of Nexletol and Nexlizet in Canada, providing treatment options for patients with elevated LDL-C levels, especially those who are statin-intolerant or not reaching their LDL-C goals with existing therapies. Esperion Therapeutics is a US-based company that develops NEXLETOL.

Regional Insights

North America was the largest region in the nexletol market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Nexletol Market?

The nexletol market consists of sales of non-statin lipid-lowering agents, dietary supplements, and cholesterol absorption inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nexletol Market Report 2026?

The nexletol market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nexletol industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.